Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.54 USD
+0.02 (0.79%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.02 (0.79%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
4 Affordable Breakout Stocks for Stunning Returns
by Nitish Marwah
Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.
Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session
by Zacks Equity Research
Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Avenue Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avenue Therapeutics
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
by Zacks Equity Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
Flexion (FLXN) Soars: Stock Adds 6.6% in Session
by Zacks Equity Research
Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide
by Zacks Equity Research
Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide
Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings
by Zacks Equity Research
Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings
How Avenue (ATXI) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pick These 5 Stocks With Superb Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
4 Breakout Stocks for Impressive Returns
by Nitish Marwah
The logic behind the breakout strategy for stock selection is to identify stocks are trading within a narrow band.
Technology on Solid Footing: 5 Stocks With More Room to Run
by Sanghamitra Saha
Tech rally is here to stay on solid fundamentals. Bet on stocks that are yet to reclaim their 52-week high levels despite the recent uptrend.
Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Top Ranked Momentum Stocks to Buy for April 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick
by Zacks Equity Research
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
by Nalak Das
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).